S. Connor

G. Mahy, M. Bastian-Jordan, S. Connor, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis

J. Andrews, I. Lawrance, G. Radford-Smith, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford

S. Travis, J. Andrews, P. Bampton, 2020, World journal of gastroenterology.

Medicinal Cannabis for Inflammatory Bowel Disease: A Survey of Perspectives, Experiences, and Current Use in Australian Patients

I. McGregor, S. Connor, C. Corte, 2020, Crohn's & colitis 360.

Ulcerative Colitis Narrative findings: Australian survey data comparing patient and physician disease management views

A. Sechi, S. Connor, J. Deuring, 2021, JGH open : an open access journal of gastroenterology and hepatology.

Inflammatory Bowel Disease Environmental Risk Factors: A Population-Based Case-Control Study of Middle Eastern Migration to Australia.

R. Gearry, S. Connor, R. Leong, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Crohn’s Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease

J. Andrews, G. Radford-Smith, A. Sechi, 2020, Scandinavian journal of gastroenterology.

Dose tailoring of anti‐tumour necrosis factor‐alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response

J. Andrews, I. Lawrance, A. Sechi, 2015, Internal medicine journal.

Survey of barriers to adherence to international inflammatory bowel disease guidelines: does gastroenterologists' confidence translate to high adherence?

A. Girgis, J. Descallar, S. Connor, 2021, Internal medicine journal.

Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel Disease

I. McGregor, S. Connor, C. Corte, 2020, Crohn's & colitis 360.

Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients’ and Physicians’ View

M. Dubinsky, J. Cappelleri, S. Connor, 2021, Inflammatory bowel diseases.

A Web-Based Decision Aid (myAID) to Enhance Quality of Life, Empowerment, Decision Making, and Disease Control for Patients With Ulcerative Colitis: Protocol for a Cluster Randomized Controlled Trial (Preprint)

J. Andrews, A. Kim, A. Girgis, 2019 .

Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease.

W. Selby, S. Travis, I. Lawrance, 2013, Journal of Crohn's & colitis.

The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus

J. Andrews, S. Connor, M. Sparrow, 2017, Internal medicine journal.

Cutting Edge: Vasoactive Intestinal Peptide Acts as a Potent Suppressor of Inflammation In Vivo by Trans-Deactivating Chemokine Receptors 1

Ji Ming Wang, S. Connor, J. Oppenheim, 2003, The Journal of Immunology.

Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost‐savings

S. Connor, W. Xuan, C. Toong, 2019, Internal medicine journal.

Environmental Risk Factors for Inflammatory Bowel Disease: A Case-Control Study in a Middle Eastern Migrant Population

R. Gearry, S. Connor, R. Leong, 2014 .

Effectiveness of fecal calprotectin testing to identify patients with organic gastrointestinal diseases: A systematic review and diagnostic meta-analysis

J. Andrews, S. Connor, J. Begun, 2019 .

Assessing effectiveness and patient perceptions of a novel electronic medical record for the management of inflammatory bowel disease

J. Andrews, S. Connor, K. Krishnaprasad, 2021, JGH open : an open access journal of gastroenterology and hepatology.

Receptors-Deactivating Chemokine Trans In Vivo by Acts as a Potent Suppressor of Inflammation Cutting Edge : Vasoactive Intestinal Peptide

Ji Ming Wang, S. Connor, J. Oppenheim, 2003 .

Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta‐analysis

J. Andrews, S. Connor, T. Neeman, 2019, The Medical journal of Australia.

Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis.

J. Clemente, J. Faith, M. Wilkins, 2019, Gastroenterology.

HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants

M. Tremelling, M. Parkes, C. Lees, 2014, Nature Genetics.

Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial

M. Kamm, T. Borody, S. Connor, 2017, The Lancet.

Gastroenterologist perceptions of faecal microbiota transplantation.

M. Kamm, T. Borody, S. Connor, 2015, World journal of gastroenterology.

Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method

Sang Hong Lee, Peter M Visscher, Naomi R Wray, 2017, BMC Medical Genetics.

Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study

G. Ahlenstiel, P. Pavli, S. Connor, 2021, BMJ Open.

Donor Recruitment for Fecal Microbiota Transplantation

Sarah Finlayson, M. Kamm, T. Borody, 2015, Inflammatory bowel diseases.

Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab.

S. Connor, W. Ng, C. Henderson, 2012, Journal of Crohn's & colitis.

Surgery for pancreatic necrosis: "whom, when and what".

J. Neoptolemos, S. Connor, 2004, World journal of gastroenterology.

An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis

G. Montgomery, J. Andrews, P. Bampton, 2021, bioRxiv.

Compassionate access anti‐tumour necrosis factor‐α therapy for ulcerative colitis in Australia: the benefits to patients

P. Bampton, A. Sechi, S. Connor, 2015, Internal medicine journal.

Menetrier’s disease exacerbating ulcerative colitis and relieved by gastrectomy

S. Connor, C. El-Haddad, W. Ng, 2021, BMJ open gastroenterology.

Proactive Metabolite Testing in Patients on Thiopurine May Yield Long-Term Clinical Benefits in Inflammatory Bowel Disease

J. Andrews, P. Bampton, A. Sechi, 2022, Digestive Diseases and Sciences.

1161 Adalimumab Prevents Post-Operative Crohn's Disease Recurrence, and is Superior to Thiopurines: Early Results From the POCER Study

Steven J Brown, M. Kamm, W. Selby, 2012 .

Colonic Epstein-Barr Virus-Associated Mucocutaneous Ulcer Associated With Ulcerative Colitis

S. Connor, N. Viiala, A. Gilmore, 2023, ACG case reports journal.

SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease

S. Connor, R. Bryant, B. Christensen, 2021, GastroHep.

Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases

J. Andrews, G. Radford-Smith, S. Connor, 2017, Alimentary pharmacology & therapeutics.

Su2092 Clinical Risk Stratification Predicts Development of Endoscopic Recurrence After Crohn's Disease Surgery: Early Results From the POCER Study

Steven J Brown, M. Kamm, W. Selby, 2012 .

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

M. Parkes, J. Satsangi, Fraser Cummings, 2023, The lancet. Gastroenterology & hepatology.

A Comparative Evaluation of Four Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies.

S. Connor, Melissa Sam, Watson Wa Sang Ng, 2020, Therapeutic drug monitoring.

Comparison of infliximab drug measurement across three commercially available ELISA kits.

S. Connor, C. Toong, W. Ng, 2016, Pathology.

P342 Adalimumab prevents post-operative Crohn's disease recurrence and is superior to thiopurines: E

Steven J Brown, W. Selby, J. Andrews, 2012 .

Tu1330 Thiopurine Metabolite Testing to Guide Management in Inflammatory Bowel Disease (IBD) Yields Clinical Benefit At 12 Months: A Retrospective Observational Study

J. Andrews, P. Bampton, A. Sechi, 2015 .

Genomic analysis of oral Campylobacter concisus strains identified a potential bacterial molecular marker associated with active Crohn’s disease

Mark M. Tanaka, S. Riordan, S. Connor, 2018, Emerging Microbes & Infections.

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

M. Kamm, T. Borody, C. Kelly, 2020, Gut.

Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study

J. Andrews, P. Bampton, R. Gearry, 2017, Alimentary pharmacology & therapeutics.

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease

S. Connor, S. Ghaly, A. Gholamrezaei, 2022, World journal of gastroenterology.

Biologic Therapeutic Drug Monitoring in Australia.

S. Connor, 2016 .

Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.

Rajvinder Singh, S. Connor, A. Zekry, 2017, Gastrointestinal endoscopy.

Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort analysis.

E. P. van der Zanden, P. Gibson, S. Connor, 2019, Journal of Crohn's & colitis.

Management Decisions in Crohn’s Disease Are Changed by Knowledge of Proactive and Reactive Testing of Antitumor Necrosis Factor Drug Levels

J. Andrews, S. Connor, Amy Wen, 2021, Crohn's & colitis 360.

Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study

J. Andrews, A. Kim, A. Girgis, 2021, Journal of medical Internet research.

Assessing the Relationship between the Gut Microbiota and Inflammatory Bowel Disease Therapeutics: A Systematic Review

S. Connor, G. Hold, T. Rokkas, 2023, Pathogens.

600 Multi Donor Intense Faecal Microbiota Transplantation is an Effective Treatment for Resistant Ulcerative Colitis: A Randomised Placebo-Controlled Trial

M. Kamm, T. Borody, S. Connor, 2016 .

Clinical and pathologic outcomes of colorectal cancer in a multi-ethnic population.

A. Kneebone, S. Connor, B. Jalaludin, 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Improved Survival in Young Women With Colorectal Cancer

A. Kneebone, S. Connor, B. Jalaludin, 2008, The American Journal of Gastroenterology.

Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits: author reply.

S. Connor, C. Toong, W. Ng, 2017, Pathology.

Safety, satisfaction and cost savings of accelerated infusions of standard and intensified‐dose infliximab for inflammatory bowel disease

S. Connor, W. Ng, Nan Wu, 2021, Internal medicine journal.

Vasodilating effect of dipyridamole on rat endoneurial vessels: morphometric study.

S. Connor, H. Nukada, 1993, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

Faecal calprotectin: current usage and perceived beneficial effects of third‐party funding on rates of colonoscopy by Australian gastroenterologists

J. Andrews, S. Connor, M. Sparrow, 2016, Internal medicine journal (Print).

Clinician Adherence to Inflammatory Bowel Disease Guidelines: Results of a Qualitative Study of Barriers and Enablers

A. Girgis, S. Connor, Ria Kanazaki, 2022, Crohn's & colitis 360.

The impact of short-term ranitidine use on the precision of the 13C-urea breath test in subjects infected with Helicobacter pylori.

S. Connor, M. Ngu, P. Katelaris, 1999, European journal of gastroenterology & hepatology.

Health Communication Research Informs Inflammatory Bowel Disease Practice and Research: A Narrative Review

S. Connor, Annabelle Lukin, A. Moore, 2023, Crohn's & colitis 360.

Clinical communication in inflammatory bowel disease: a systematic review of the study of clinician–patient dialogue to inform research and practice

S. Connor, Annabelle Lukin, A. Moore, 2021, BMJ Open.

Tu1331 Are We Under-Recognizing Skewed Thiopurine Metabolism in IBD Patients? Routine Thiopurine Metabolite Measurement Yields Clinical Benefit at 12 Months: A Retrospective Observational Study

J. Andrews, P. Bampton, A. Sechi, 2015 .

Chemokine receptor expression and function in lamina propria mononuclear cells of the human colon

S. Connor, M. Grimm, A. Lloyd, 2000 .

Donor Recruitment for Fecal Microbiota Transplantation

M. Kamm, T. Borody, S. Connor, 2015, Inflammatory bowel diseases.

Inflammatory Bowel Disease Environmental Risk Factors: A Population-Based Case-Control Study of Middle Eastern Migration to Australia.

R. Gearry, S. Connor, R. Leong, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Adolescents and young adults communicating with gastroenterologists: variation in inflammatory bowel disease clinical communication

S. Connor, Annabelle Lukin, V. Kariyawasam, 2023, International journal of adolescent medicine and health.

1029 WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL

S. Connor, R. Paramsothy, P. De Cruz, 2023, Gastroenterology.

Adalimumab and infliximab levels in neonates (ERA study)

R. Gearry, G. Radford-Smith, S. Connor, 2015 .